Evidence map›Paper›PMID 28926105›Full record

ArticleJournal of cellular physiology2018

Loss of RUNX1 is associated with aggressive lung adenocarcinomas.

Jon Ramsey, Kelly Butnor, Zhihua Peng, Tim Leclair, Jos van der Velden, Gary Stein, Jane Lian, C Matthew Kinsey

Abstract read
In one paragraph

Article in Journal of cellular physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Runt-related transcription factors in human carcinogenesis: a friend or foe?Journal of cancer research and clinical oncology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Clinicopathological Significance ofJournal of clinical medicine · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jon RamseyDepartment of Biochemistry, University of Vermont, Burlington, Vermont.
Kelly ButnorDepartment of Pathology, University of Vermont Medical Center, Burlington, Vermont.
Zhihua PengDepartment of Pathology, University of Vermont Medical Center, Burlington, Vermont.
Tim LeclairDepartment of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Jos van der VeldenDepartment of Pathology, University of Vermont Medical Center, Burlington, Vermont.
Gary SteinDepartment of Biochemistry, University of Vermont, Burlington, Vermont.
Jane LianDepartment of Biochemistry, University of Vermont, Burlington, Vermont.
C Matthew KinseyPulmonary and Critical Care, University of Vermont Medical Center, Burlington, Vermont.ORCID 0000-0003-2124-3709
University of Vermont Medical Center · USUniversity of Vermont · USBeth Israel Deaconess Medical Center · US

Funding

GSTP1-induced S-glutathionylation in lung cancerR01CA219156 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI VAN DER VELDEN, ADRIANUS (JOS)L.J. · 2017 to 2021
$1.8M
CT Characteristics of Emphysema for Evaluation of Pulmonary NodulesK23HL133476 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI KINSEY, CHARLES MATTHEW · 2016 to 2021
$933k
NCI NIH HHS L30 CA189136NCI NIH HHS R01 CA219156NHLBI NIH HHS K23 HL133476
6 · The paper itself

Abstract

The mammalian runt-related factor 1 (RUNX1) is a master transcription factor that regulates lineage specification of hematopoietic stem cells. RUNX1 translocations result in the development of myeloid leukemias. Recently, RUNX1 has been implicated as a tumor suppressor in other cancers. We postulated RUNX1 expression may be associated with lung adenocarcinoma etiology and/or progression. We evaluated the association of RUNX1 mRNA expression with overall survival data from The Cancer Genome Atlas (TCGA), a publically available database. Compared to high expression levels, Low RUNX1 levels from lung adenocarcinomas were associated with a worse overall survival (Hazard Ratio = 2.014 (1.042-3.730 95% confidence interval), log-rank p = 0.035) compared to those that expressed high RUNX1 levels. Further immunohistochemical examination of 85 surgical specimens resected at the University of Vermont Medical Center identified that low RUNX1 protein expression was associated with larger tumors (p = 0.038). Gene expression network analysis was performed on the same subset of TCGA cases that demonstrated differential survival by RUNX1 expression. This analysis, which reveals regulatory relationships, showed that reduced RUNX1 levels were closely linked to upregulation of the transcription factor E2F1. To interrogate this relationship, RUNX1 was depleted in a lung cancer cell line that expresses high levels of RUNX1. Loss of RUNX1 resulted in enhanced proliferation, migration, and invasion. RUNX1 depletion also resulted in increased mRNA expression of E2F1 and multiple E2F1 target genes. Our data implicate loss of RUNX1 as driver of lung adenocarcinoma aggression, potentially through deregulation of the E2F1 pathway.

Indexed as

AggressionCore Binding Factor Alpha 2 SubunitGene Expression RegulationLung NeoplasmsAdenocarcinoma of LungCell ProliferationGene Expression ProfilingHematopoietic Stem CellsHumansTranscriptional ActivationCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanadenocarcinomanon-small cell lung cancerrunt related transcription factorRUNX

Identifiers

PMID28926105
PMCPMC5989135
OpenAlexW2754682299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.